MGNX News and Press, MacroGenics Inc. From 08/09/23

Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data...

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its ...

2023-05-29 02:47:12 ET Summary MacroGenics demonstrates promise with its drug lorigerlimab for mCRPC treatment, despite a recent 18% stock price drop. Q1 2023 showed financial growth for the company, with doubled revenue and a narrower net loss compared to Q1 2022. FDA's appro...

2023-05-10 00:30:40 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q1 2023 Earnings Call May 09, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q1 2023 Earnings Call Transcript

2023-05-09 20:16:05 ET MacroGenics, Inc. (MGNX) Q1 2023 Results Conference Call May 09, 2023 04:30 PM ET Company Participants Jim Karrels - Vice President, Chief Financial Officer Scott Koenig - President and CEO Conference Call Participants Jonathan Chan...

2023-05-09 16:27:10 ET MacroGenics press release ( NASDAQ: MGNX ): Q1 GAAP EPS of -$0.61 misses by $1.20 . Revenue of $24.5M (+120.7% Y/Y) misses by $71.66M . Shares -4.9% . Cash, cash equivalents and marketable securities as of March 31, 2023, wer...

ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC) Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nin...

2023-05-08 14:58:56 ET MacroGenics ( NASDAQ: MGNX ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is $0.35 (vs. -$1.08 last year) and the consensus Revenue Estimate is $96.16M (vs. $11.1M last year). Ov...

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial result...

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration&#...